A Prostate Cancer Marker Panel
Author Information
Author(s): Nakagawa Tohru, Kollmeyer Thomas M., Morlan Bruce W., Anderson S. Keith, Bergstralh Eric J., Davis Brian J., Asmann Yan W., Klee George G., Ballman Karla V., Jenkins Robert B.
Primary Institution: Mayo Clinic
Hypothesis
An expression biomarker panel can predict which men with a rising PSA would benefit from further therapy.
Conclusion
Specific gene expression patterns are significantly associated with systemic progression after PSA recurrence.
Supporting Evidence
- The model generated an AUC of 0.88.
- Genes mapped to 8q24 were significantly enriched in the model.
- The model predicted prostate cancer death with a hazard ratio of 2.5.
Takeaway
Researchers created a test to see which men with rising PSA levels after prostate cancer treatment might need more therapy, based on their gene patterns.
Methodology
A nested case-control study design was used to test the association of gene expression with outcome, evaluating 1021 cancer-related genes.
Potential Biases
The study may have biases related to the selection of cases and controls from a single institution.
Limitations
The accuracy of the model decreased when tested on a validation set, indicating potential overfitting.
Participant Demographics
Men who underwent radical retropubic prostatectomy for prostate cancer, with a median age of 67.
Statistical Information
P-Value
p<0.0005
Confidence Interval
95% CI: 0.84–0.92
Statistical Significance
p<0.0005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website